US-IVD
cobas® KRAS Mutation Test
IVD
For in vitro diagnostic use.

Use left and right arrow keys to scroll between the tabs
Identifies mutations in codons 12, 13 and 61 of the KRAS gene
The cobas® KRAS Mutation Test offers broad mutation coverage of KRAS codons 12, 13 and 61 to identify colorectal cancer patients who are not likely to respond to anti-EGFR monoclonal antibody therapies.
Features and benefits
- The cobas® KRAS Mutation Test detects major mutations in codons 12, 13 and 61 from colorectal cancer patients
- In formalin-fixed, paraffin-embedded tissue (FFPET), the cobas® KRAS Mutation Test can detect <5% mutant sequence copies in a background of wild-type DNA
- Robust, reliable KRAS test results can be obtained from a single, 5µm FFPET section with >10% tumor content using the cobas® KRAS Mutation Test
- The test can be performed in <8 hours so results can be reported to the treating physician within a few days from laboratory receipt of specimen
- Liquid, ready-to-use reagents increase laboratory efficiency
- Automated result interpretation and test reporting provides consistent, objective and reproducible results from laboratory to laboratory
Registration status
Would you like to know more about the cobas® KRAS Mutation Test?
Please submit your information in the following form to be contacted by a Roche representative with more details.